In addition, a phase II clinical trial in AR-positive/ER-negative advanced breast cancer patients with the AR antagonist bicalutamide demonstrated a clinical benefit rate of 19% at six months with an improved progression free survival of 12 weeks (194). Here, AR is linked to breast carcinoma.